Analysts at StockNews.com started coverage on shares of Pulmatrix (NASDAQ:PULM – Get Free Report) in a report issued on Saturday. The brokerage set a “hold” rating on the biotechnology company’s stock.
Pulmatrix Price Performance
Shares of PULM stock opened at $2.13 on Friday. The firm has a 50-day moving average of $2.07 and a 200-day moving average of $2.03. Pulmatrix has a one year low of $1.55 and a one year high of $2.75. The company has a market cap of $7.78 million, a P/E ratio of -0.72 and a beta of 1.00.
Pulmatrix (NASDAQ:PULM – Get Free Report) last posted its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.87) EPS for the quarter. Pulmatrix had a negative return on equity of 46.86% and a negative net margin of 95.18%. The firm had revenue of $1.55 million for the quarter.
Pulmatrix Company Profile
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
See Also
- Five stocks we like better than Pulmatrix
- About the Markup Calculator
- Energy Vault Soars 100%: CEO Shares Why in MarketBeat Exclusive
- Best Stocks Under $10.00
- Meta’s Q3 Earnings Beat—Is This Dip a Golden Entry Opportunity?
- Bank Stocks – Best Bank Stocks to Invest In
- Top Nuclear Stocks Thriving on Soaring Energy Demand
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
